Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

Journal of the National Cancer Institute

Volumn 90, Issue 24, 1998, Pages 1894-1900

  Rosenberg, Steven A ^a,c   Zhai, Yifan ^a   Yang, James C ^a   Schwartzentruber, Douglas J ^a   Hwu, Patrick ^a   Marincola, Francesco M ^a   Topalian, Suzanne L ^a   Restifo, Nicholas P ^a   Seipp, Claudia A ^a   Einhorn, Jan H ^a   Roberts, Bruce ^b   White, Donald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENZYME CORPORATION   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; INTERLEUKIN 2; MELANOMA ANTIGEN; PARACETAMOL; RANITIDINE; TUMOR ANTIGEN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADENOVIRUS; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HUMAN; HUMAN CELL; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MELANOMA; MELANOMA CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT;

EID: 0032539190     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.24.1870-b     Document Type: Article

References (14)

1. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996;88:1635-44.
2. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18: 175-82.
3. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994;191:6458-62.
4. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
5. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180: 35-12.
6. Rosenberg SA. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J Sci Am 1995;1:89-100.
7. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-l/Melan A. Cancer J Sci Am 1997;3: 37-44.
8. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
9. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola MF, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
10. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996;156: 224-31.
11. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154: 5282-92.
12. Rubin BA, Rorke LB. Adenovirus vaccines. In: Plotkin SA, Mortimer EA, editors. Vaccines. Philadelphia (PA): Saunders; 1994. p. 475-502.
13. Imler JL. Adenovirus vectors as recombinant viral vaccines. Vaccine 1995;13:1143-51.
14. Top FH Jr. Control of adenovirus acute respiratory disease in U.S. Army trainees. Yale J Biol Med 1975;48:185-95.